Aditya Juloori, MD

Articles

Clinical Utility of ctDNA in Guiding Perioperative Treatment Decisions in Early-Stage NSCLC

July 29th 2025

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for identifying patients at higher risk who may benefit from therapy escalation, though they acknowledge the current lack of prospective data on how to act therapeutically on positive ctDNA results.

Optimizing Adjuvant Therapy Decisions in Resectable NSCLC: Integrating Pathologic Response, PD-L1, and Nodal Status

July 29th 2025

Panelists discuss how treatment decisions should integrate multiple factors, including pathologic complete response (pCR), PD-L1 status, and nodal involvement, with particular emphasis on continuing adjuvant therapy for N2 disease and non-PCR patients despite the complexity of using residual viable tumor as a decision-making tool.

FDA Green-Lights Subcutaneous Nivolumab: What It Means for Early-Stage NSCLC Care

July 22nd 2025

Panelists discuss how subcutaneous (SQ) nivolumab administration offers patient convenience and potential logistical advantages, particularly in the maintenance setting, though they acknowledge limited current adoption and need for more biological data on efficacy differences.

MDT Management of Borderline Resectable Early-Stage NSCLC and Delayed Surgery After Neoadjuvant IO

July 22nd 2025

Panelists discuss how borderline resectable patients can be made resectable through neoadjuvant chemoimmunotherapy when surgeons have clear, objective goals for what they aim to achieve rather than vague hopes to make surgery “less scary.”

Expert Perspectives in Challenging Situations: Progression After Neoadjuvant Chemoimmunotherapy

July 15th 2025

Panelists discuss how to manage patients who cannot proceed to surgery after neoadjuvant chemoimmunotherapy by pivoting to definitive concurrent chemoradiation with reduced-dose chemotherapy, while emphasizing the need to distinguish true progression from inflammatory changes.

ASCO 2025 Real-World Data on Neoadjuvant Therapy in Stage II to III NSCLC: Surgical Outcomes and Clinical Implications

July 15th 2025

Panelists discuss how real-world data from the Flatiron Health database revealed that surgical completion rates after neoadjuvant therapy are lower in community practice (65%) compared with clinical trials, particularly for patients with poor performance status or more advanced stage disease.

Surgical Perspectives: Who Are the Best Candidates for Neoadjuvant Chemoimmunotherapy?

July 8th 2025

Panelists discuss how surgeons evaluate candidates for neoadjuvant chemoimmunotherapy by emphasizing that all patients with stage II and III disease should be considered regardless of PD-L1 or mutation status, while highlighting the importance of multidisciplinary collaboration in treatment decisions.

CheckMate 77T: Updated Survival and Biomarker Insights Shaping Early-Stage NSCLC Care

July 8th 2025

Panelists discuss how the CheckMate 77T perioperative trial updates showed that even patients receiving fewer than 4 cycles of neoadjuvant therapy still benefited, and circulating tumor DNA (ctDNA) clearance serves as an independent biomarker for predicting outcomes regardless of pathologic response status.

CheckMate 816 at ASCO 2025: OS Update and Impact on Early-Stage NSCLC Care

June 27th 2025

Panelists discuss how the CheckMate 816 overall survival data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated a significant survival benefit with neoadjuvant chemoimmunotherapy, particularly in patients with higher PD-L1 expression and those achieving pathologic complete responses (pCRs).

Resectable Early-Stage NSCLC: How the Standard of Care Is Evolving

June 27th 2025

Panelists discuss how the standard of care for resectable early-stage non–small cell lung cancer (NSCLC) has evolved from adjuvant chemotherapy alone to neoadjuvant chemoimmunotherapy and perioperative approaches that combine preoperative treatment with continued immunotherapy after surgery.

Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

August 8th 2024

The panel discusses treatment considerations for consolidation durvalumab.

Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

August 8th 2024

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

August 8th 2024

The panel looks at a second patient case study.

Management of Resectable Early Stage NSCLC with Actionable Mutations

August 8th 2024

The panel discusses management of resectable early-stage non–small cell lung cancer.

Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

August 8th 2024

The panel discusses the factors that go into selecting patients for adjuvant therapy.

Management of Borderline Resectable NSCLC

August 8th 2024

The panel discusses reassessing for respectability after certain treatments.

Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC

July 12th 2024

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

July 12th 2024

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

June 25th 2024

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

June 25th 2024

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.